… osteoporosis, but also have opened doors of opportunity to improvements in the effective
treatment. However, the high cost of new … early diagnosis of osteoporosis and understanding of …

… In conclusion, odanacatib is a potential new antiresorptive treatment of osteoporosis with
an anti-fracture efficacy comparable to current treatments. The drug still awaits approval by the …

… Osteoporosis is a disease characterized by low bone mass … One of the major challenges in
the management of osteoporosis lies … Furthermore, osteoporosis often remains undiagnosed …

… The prevalence of osteoporosis in the world was reported to be 18.3%, and the economic
burden of osteoporosis-related fracture reaches approximately $17.9 and £4 billion per annum …

… the new horizons in bone health and osteoporosis … , the skeletal structure and nature of
osteoporosis, as well as the … challenges and limitations of osteoporosis diagnosis, best practice …

… Approximately 15% to 36% of RA patients develop systemic osteoporosis due to an … effects
on osteoporosis in RA patients. Dmab treatment prevents bone erosion and osteoporosis in …

… There are several investigational approaches on the horizon for the treatment of osteoporosis.
While current treatments are focused on the use of antiresorptive and anabolic agents that …

… knowledge and instruments to tackle the ongoing osteoporosis crisis. In the present review,
… related to osteoporosis in the next decade and we will discuss on the future of osteoporosis …

… to new therapies exemplified by the development of monoclonal antibodies for osteoporosis…
cells will lead to new small molecules made for osteoporosis treatment, perhaps causing …

… lasts only 1–2 min and allows the evaluation not only of the bone density changes during
a disease process but also after pharmacologic intervention for the treatment of osteoporosis. …